Skip to content

Market explorer

Screen the results we have checked

Search and filter our published results. This is selected coverage, not a screen of every listed stock.

Read the basis before comparing. Revenue is the company's reported revenue line, not a standardised comparable measure. Excise, acquisitions, exceptional items and different reporting periods can change growth. Missing revenue or growth is not zero. Each result below keeps its filing basis and caveats. No live prices, valuation filters or recommendations.

1 matching results out of 156 published entries. 69 have revenue growth available.

Aurobindo Pharma

Growth unavailable

Q2 FY2027 · Period ended 30 Sep 2026

Basis: Consolidated, as stated in the company's Q2 FY2027 press release dated 4 Nov 2026

Reported revenue (₹ crore, except margin): 10,263

Read summary and comparison caveats

Aurobindo Pharma reported September-quarter consolidated revenue from operations of ₹10,263 crore, with printed growth of 23.9% year on year and 12.2% sequentially. EBITDA before forex and other income was ₹2,156 crore. The release labels net profit for the period at ₹1,124 crore, compared with ₹848 crore a year earlier. The release-based EBITDA margin was 21.0%.

  • The five-page company press release dated 4 Nov 2026 was read in full on 17 Nov; its headline table was visually checked. This entry uses the rounded consolidated press-release table, not standalone or half-year figures. It is not a substitute for the signed financial statement and review report.
  • Amounts are already in INR crore in this release. No unit conversion or percentage calculation is applied. Year ago is Q2 FY2026; previous quarter is Q1 FY2027. All growth percentages and basis-point changes shown above are printed in the source.
  • EBITDA is explicitly before forex and other income; PBT is explicitly before share of profit/loss of joint ventures. These labels are retained and are not treated as statutory total PBT or interchangeable profit measures.
  • The release calls ₹1,124 crore net profit for the period without a separate non-controlling-interest reconciliation in its headline table. That label is retained, rather than inferring profit attributable to owners or adjusted PAT. The release does not provide an exceptional-item reconciliation; none is invented here.
  • The margin table prints 21.0% versus 20.3% and 20.6%, with changes of 75 bps and 45 bps. Printed basis-point changes are retained, not recalculated from rounded displayed margins.
  • The release describes growth supported by organic performance and integration of inorganic opportunities. This table is not a like-for-like organic-growth calculation. Forward-looking management comments, cash-flow claims, product approvals and dividend information are not used as earnings measures.
  • Selected own-source coverage, not complete market coverage. The restricted investor presentation was not used; this entry is original factual prose from the separately published press release.

Checked 17 Nov 2026

Open original filing
Read the complete published results desk